We are live on ! Find out more
TVRD

Tvardi Therapeutics

92 hedge funds and large institutions have $266M invested in Tvardi Therapeutics in 2015 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 41 increasing their positions, 18 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 8

128% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 18

123% more call options, than puts

Call options by funds: $507K | Put options by funds: $227K

81% more capital invested

Capital invested by funds: $147M → $266M (+$119M)

23.87% more ownership

Funds ownership: 44.42%68.29% (+24%)

23% more funds holding

Funds holding: 7592 (+17)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
92
Holders Change
+17
Holders Change %
+22.67%
% of All Funds
2.56%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
25
Increased
41
Reduced
18
Closed
8
Calls
$507K
Puts
$227K
Net Calls
+$280K
Net Calls Change
-$184K

TVRD Hedge Fund Activity: Q3 2015 in Review

92 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q3 2015, worth a combined $266M — up 81% from $147M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new TVRD positions and 8 closed out — a net gain of 17 holders — while 41 added to existing stakes and 18 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $51M. The largest seller was Wall Street Associates, cutting an estimated $4.53M.

  • 92 institutional investors held Tvardi Therapeutics (TVRD) as of Q3 2015, up from 75 in Q2 2015.
  • Funds reported $266M of Tvardi Therapeutics stock for Q3 2015, up 81% quarter-over-quarter.
  • 25 funds opened new Tvardi Therapeutics positions in Q3 2015 and 8 closed out, a net change of +17 holders.
  • The largest Tvardi Therapeutics buyer in Q3 2015 was Fidelity Investments, an estimated $51M added.
  • The largest Tvardi Therapeutics seller in Q3 2015 was Wall Street Associates, an estimated $4.53M sold.

Based on aggregated 13F filings for Q3 2015.